IMGN

Immunogen Inc

A maker of antibody-drug conjugates, a type of targeted cancer therapy that pairs a homing antibody with a cell-killing payload. Its technology helped create the breast-cancer drug Kadcyla and its own FDA-approved medicine Elahere treats ovarian cancer. Founded in 1981, the Massachusetts biotech was acquired by AbbVie in 2024. Its name blends "immuno" (antibodies) with "gen," reflecting its focus on generating antibody-based therapies.